NeoGenomics Shares Rise 5% in 1 Day Since Earnings Call

Key highlights

• Total revenue reached $201.7 million for the second quarter, representing an 11 percent increase year-over-year
• Clinical services revenue rose 14 percent to $187 million, supported by a 12 percent increase in average unit price
• Next-Generation Sequencing revenue grew by 26 percent, now comprising approximately one-third of clinical revenue
• Management raised full-year 2026 revenue guidance to a range of $802 million to $806 million
• Adjusted EBITDA increased by 36 percent year-over-year to $14.4 million
• Commercial operations were reorganized into dedicated oncology and pathology ecosystems to improve market alignment

Financial Performance

Total revenue for the second quarter was $201.7 million, an 11 percent increase over the same period last year and approximately $4 million above prior management guidance. The primary driver of this performance was the clinical segment, which saw revenue grow 14 percent to $187 million. This increase was attributed to a 2 percent growth in test volumes coupled with a 12 percent rise in average unit price, resulting from improved test mix and revenue cycle management. Gross margins also showed strength, with adjusted gross margin reaching 48.1 percent. Adjusted EBITDA rose to $14.4 million, benefiting from top-line growth and effective operating expense discipline.

Down 12.9% since our story on 5 Oct: $19.13 when we broke it → $16.66 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$18.41
15 Sep	$18.89
16 Sep	$18.94
17 Sep	$19.89
18 Sep	$19.91
21 Sep	$19.41
22 Sep	$18.89
23 Sep	$18.36
24 Sep	$19.56
25 Sep	$19.33
28 Sep	$19.29
29 Sep	$18.74
30 Sep	$18.36
1 Oct	$17.78
2 Oct	$18.47
5 Oct	$19.13
6 Oct	$16.51
7 Oct	$15.97
8 Oct	$16.02
9 Oct	$16.35
12 Oct	$16.20
13 Oct	$16.66

Management Outlook

Following the strong quarterly results, NeoGenomics raised its full-year 2026 revenue guidance to between $802 million and $806 million. The company expects clinical growth to remain in the low teens for the remainder of the year, with Next-Generation Sequencing growth forecasted in the mid-20 percent range. Management has adjusted expectations for the non-clinical and pharma segment, which is now anticipated to decline in the high single digits for the full year. However, the company is targeting a return to year-over-year growth for the entire non-clinical segment by 2027.

Business Overview

NeoGenomics is a specialized oncology reference laboratory providing diagnostic, prognostic, and predictive testing services. The company operates a network of testing facilities that serve oncologists, pathologists, and pharmaceutical companies. Its portfolio includes advanced genomic testing such as Next-Generation Sequencing and minimal residual disease monitoring assays like RaDaR ST. To support long-term growth, the company recently reorganized its commercial team into two distinct ecosystems focused on pathology and oncology to better serve its varied client base.

Sector Dynamics

The healthcare diagnostics sector is currently defined by a divergence between clinical demand and pharmaceutical services. While demand for high-value genomic testing and oncology diagnostics remains robust in clinical settings, the pharmaceutical segment has faced broader industry headwinds that have slowed biopharma-related testing growth. Regulatory progress, particularly regarding Medicare reimbursement coverage for new cancer indications and minimal residual disease assays, remains a critical factor for market expansion in the oncology diagnostic space.

What to Watch

• Further Medicare reimbursement approvals for additional RaDaR ST solid tumor indications
• Execution of the revised full-year revenue guidance between $802 million and $806 million
• Performance of the reorganized oncology and pathology commercial ecosystems
• The timeline for stabilization and recovery in the pharmaceutical services segment
• Continued margin expansion through the Lab of the Future operational initiatives

Strategic Commentary

“We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year.”

Management commentary

“Total revenue in the quarter was $201.7 million, up 11% year-over-year.”

“Adjusted EBITDA was $14.4 million, up 36% year-over-year.”

NeoGenomics, Inc. · financial snapshot

Share price	$19.13
Market cap	$2.5B
Revenue (annual)	$727M
1-month price change	+9.94%
Sector	HealthcareDiagnostics & Research

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.